Genelux Corporation is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for patients with aggressive and difficult-to-treat solid tumors. The company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary modified strain of the vaccinia virus designed for systemic and intratumoral delivery, with primary clinical focus on platinum-resistant/refractory ovarian cancer. Pipeline assets are derived from Genelux's proprietary CHOICE discovery platform, an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic candidates. Founded in 2001 and headquartered in Westlake Village, California, Genelux IPO'd on Nasdaq under ticker GNLX in January 2023.
Genelux is publicly traded
IPO'd on Jan 26, 2023
This company is no longer available on our private secondary market. Shares can be traded publicly under GNLX.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2001
Employees
11–50
Total Funding
$66M
4 rounds
Follow-on offering of 6,666,667 shares at $3.00 priced Jan 8, 2026 and closed Jan 9; $18.5M net confirmed in Form 10-K
Post-listing shelf takedown, not a private round; pro forma cash of $33.1M funds operations into 1Q27
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $66M across 4 rounds
Last updated 10-01-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| May 23, 2024 | Post-IPO Equity (Public Offering) Press release | $30.0M | — | |
| May 15, 2023 | Private Placement (PIPE) Press release | $33M | — | |
| Jan 26, 2023 | IPO | $15M | — |
Thomas Zindrick
Chairman, President & Chief Executive Officer
Matt Pulisic
Chief Financial Officer
Jason Litten
Chief Medical Officer
Tony Yu
Chief Scientific Officer
Joseph Cappello
Chief Technical Officer
Eric Groen
General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Replimune
Clinical-stage company developing intratumoral HSV-1-based oncolytic immunotherapies (RP1, RP2, RP3) for solid tumors.
Candel Therapeutics
Late clinical-stage biopharma developing adenovirus- and HSV-based oncolytic viral immunotherapies for prostate, pancreatic, and lung cancers.
CG Oncology
Clinical-stage biotech advancing cretostimogene grenadenorepvec (CG0070), an intravesical oncolytic adenovirus immunotherapy for non-muscle invasive bladder cancer.
Oncolytics Biotech
Clinical-stage biotech developing pelareorep, an intravenously delivered reovirus-based oncolytic immunotherapy for breast, pancreatic, and other solid tumors.
Imugene
Clinical-stage immuno-oncology company with an oncolytic virotherapy platform (CF33/Vaxinia) and other cancer immunotherapy candidates.
Targovax
Clinical-stage immuno-oncology company developing oncolytic virus immunotherapies (ONCOS-102) for solid tumors including mesothelioma and melanoma.
Yes, Genelux is publicly traded under the ticker symbol GNLX on the NASDAQ. The company went public in Jan 26, 2023.
Genelux trades under the ticker symbol GNLX on the NASDAQ. It began trading in Jan 26, 2023.
Genelux (GNLX on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker GNLX to place an order.
Genelux went public in Jan 26, 2023 via ipo. Genelux has traded on the Nasdaq Capital Market under the ticker GNLX since its January 26, 2023 initial public offering, which priced 2,500,000 shares at $6.00 per share for gross proceeds of approximately $15.0 million. On January 8, 2026 the company priced an underwritten follow-on public offering of 6,666,667 shares at $3.00 per share off an effective Form S-3 shelf registration statement, with Lucid Capital Markets as sole book-running manager, raising approximately $20.0 million in gross and $18.5 million in net proceeds on closing the following day. Cash, cash equivalents, marketable securities and restricted cash stood at $18.7 million at June 30, 2026, which the company expects to fund operations into the first quarter of 2027, with topline Phase 3 data for Olvi-Vec in platinum-resistant/refractory ovarian cancer anticipated in the second half of 2026.
Genelux raised $66M across 4 disclosed funding rounds prior to its public listing.
Genelux is headquartered in Westlake Village, CA, USA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.